The recent technological advancement in the field of next-generation sequencing (NGS) and cell and molecular biology has given birth to the new era of precision medicine, which offers a platform to analyze the variability in genes, lifestyle, and environment of each person individually. Now, the researchers have found an even better option through cell sequencing, which precedes the advancements of next-generation sequencing. In the past few decades, whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) methods have been applied to single cells to combine DNA, RNA, protein, and chromatin information through a single cell. The transcriptomics technique has enabled researchers to use genomics, proteomics, transcriptomics, and epigenomics to understand the heterogeneity of genetically identical cells in the same tissue. The paradigm-shift from bulk cell sequencing to DR-seq (DNA and mRNA sequencing) and G&T-seq (genome and transcriptome), scM&T-seq (simultaneous single-cell methylome and transcriptome sequencing), scNMTseq (single-cell nucleosome, methylation, and transcription sequencing) enable to broaden the understanding of genotypic and phenotypic heterogeneity by using multi-omics approach. Information from different omics platforms can be integrated through this approach, making available deep insights on the effect of these omics’ layers on the underlying mechanisms of disease processes.

The research service will provide an overview of the global wound care solutions market, the competitive landscape, impact of COVID-19, and others. The geographical scope of this global study will be focused on three key regions namely, North America (NA), Europe, Asia-Pacific (APAC) and Rest of world (RoW). This study will provide a six-year global market revenue forecast from 2021 to 2026. This research service will offer a detailed segment analysis of the advanced wound care solutions, including the various next-generation solutions that are set to dominate the market. It will not cover basic and surgical wound care solutions. Wound care products related to pharmaceuticals and life sciences are also excluded from the study scope. The forecast for this study covers the wound care continuum approach comprising wound prevention and diagnosis solutions and wound management solutions.

The prevalence of several chronic diseases worldwide and the launch of sophisticated technologies and treatments have contributed to a rapid increase in healthcare expenses. Additionally, patients nowadays expect high-quality care at an affordable cost. Thus, it has become imperative for players in the healthcare industry to reduce the cost of their healthcare services while providing high-quality care to patients. Efficient healthcare logistics services provide a remarkable opportunity for controlling healthcare costs through the implementation of best practices. Moreover, the need for an effective flow of materials and information has been evident throughout history. In the healthcare business, materials and goods are always on the move. Hospitals and healthcare centers have huge central warehouses, small parts storage units, and everything in between. In healthcare warehousing, the biggest challenges entail supervising products with due dates, optimizing item titles, and enhancing processes while ordering supplies. Proper inventory management and the smooth movement of necessary healthcare products within the hospital premises may result in considerable savings instead of frequent new product orders.

The CRO market comprises services segmented into nonclinical and clinical based on the drug development stage. Some services, such as bioanalytical services, are peripheral services spanning both nonclinical and clinical drug development stages. This study focuses only on the broad core services in the CRO industry. The nonclinical segment includes drug discovery services and preclinical services. Further subsegments are not included in this study.

生物制药上游行业技术壁垒高，客户粘性强。生物制药上游行业包括下游科研、研发、生产所需的仪器、设备、原料和耗材，涉及物理、材料、电子、生物等多学科交叉，该行业产品种类丰富，研发难度大，技术壁垒高。产品注册制度导致下游用户更换核心原料、生产设备的成本高、代价大，因此客户对上游供应商选择谨慎，用户粘性强，行业护城河宽。

硬镜用于微创外科手术的术中成像，微创手术已成为多类疾病的金标准术式，微创手术的繁荣不断丰富内窥镜的种类，应用场景多元化。技术和术式创新，书写百年硬镜诊疗史，内窥镜的发展促进微创手术的发展，同时微创手术的进步对内窥镜提出了更高的要求，相互促进、正向循环。

日内瓦药品专利池(MPP)组织宣布，已与27 家仿制药企业签署协议，生产默克口服COVID-19 抗病毒药物molnupiravir，并向105 个低收入和中等收入国家供应。中国药企中，博瑞医药、复星医药、迪赛诺、龙泽制药、朗华制药（维亚生物）5 家入选。

截至2021年11月12日，医药生物行业下跌6.4%，子版块医疗服务II上涨。医药板块分化，疫情受益及CXO板块表现突出，集采之下仿制药及高值。

行业内规模最大的摩根大通健康医疗大会在线上进行，GSK、Pfizer、BMS 等国际巨头均有参与，国内众多药企也有参与，选取国内十三家药企的演讲内容进行精要总结，包含国内大药企的管线布局、国际化进展，Biotech 公司核心产品的战略规划、适应症布局、2022 年关键临床时间节点，以及未上市但具备差异化技术的公司。

早在2017年，国内医药健康类大平台就开展了区块链项目，当时将常州市作为试点城市，欲将区块链技术与产业相结合，利用区块链的特性，实现医疗数据共享，并采用现代化且安全可靠的新兴方式，解决医疗信息中的信息孤岛问题。基于采用区块链的不可篡改特征、监控药品的流动以及保证数据安全等方面的考虑，除了区块链用于医疗信息当中的电子病历数据、个人健康数据、临床科研数据等共享应用之外，区块链技术在药品溯源方面的应用也开展起来。当然，该技术本身也存在很多问题，其中，对于数据的处理速度、资源使用效能是突破的重点。